On World Arthritis Day, TOGETHER-PsA data and 3 rheumatology/derm experts frame GLP-1 agonists as a promising — but not yet proven — adjunct therapy.
|Slideshows|October 30, 2021
Endocrine Month in Review: October 2021
Advertisement
Editor's Note: Clicking in the center of a slide will redirect you to the article highlighted within that slide.
Top Stories of October 2021:
ADA and EASD Publish Guidance on Diagnosis, Management of Type 1 Diabetes
Published on September 30, the consensus report provides perspective on diagnosis and management of type 1 diabetes, including a diagnosis algorithm and insight on CGM specific to type 1 diabetes, which the writing group noted is lacking from previous guidance.PTH Tablets Could Provide Oral Option for Osteoporosis Management
A phase 2 trial presented at ASBMR provides insight into the effects of oral PTH tablets on bone health among postmenopausal women with osteoporosis.Statin Initiation Could Contribute to Worsening Diabetes in Type 2 Diabetes
Analysis of data from 83k matched pairs suggests statin initiation could increase a patient's odds of diabetes progression, including need for new glucose-lowering medications and new insulin use.Around the Practice: Diabetes Management in 2021
A panel of experts discuss the management of diabetes in 2021, with segments dedicated to using new technologies, management of cardiovascular comorbidities, and management of renal impairment.
Advertisement
Related to this article
At Week 52, ixekizumab plus tirzepatide sustained gains in skin clearance, joint response and metabolic measures versus ixekizumab alone.
Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
Amgen reported dazodalibep met its primary endpoint in the phase 3 OASIZ-301 trial, improving ESSDAI score in moderate-to-severe systemic Sjögren's disease.
Rozanolixizumab improved FIQR score at 10 weeks but did not reach 2-sided statistical significance on its primary BPI-SF interference endpoint.
Two-year data from the open-label extension show sustained ACR and MDA response rates for the TYK2 inhibitor in active psoriatic arthritis.
Advertisement
Advertisement